{"id":1013090,"date":"2026-10-23T08:06:48","date_gmt":"2026-10-23T12:06:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/"},"modified":"2026-10-23T08:06:48","modified_gmt":"2026-10-23T12:06:48","slug":"niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/","title":{"rendered":"Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <i>Agreement brings CAP and NYS CLEP-approved genotyping test to a multi-site Alzheimer\u2019s clinical research network<\/i>\n      <\/p>\n<p>\n        <b>PRINCETON, NJ, NEW HAVEN, CT and ORLANDO, FL, Oct.  23, 2026  (GLOBE NEWSWIRE) &#8212;  <\/b>Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs through advanced genomic and biomarker testing, today announced that DiamiR Biosciences, its wholly owned subsidiary, has signed an agreement to perform apolipoprotein E (<i>APOE<\/i>) genotyping for Charter Research, a multi-site clinical research organization that conducts trials in Alzheimer\u2019s disease, Parkinson\u2019s disease, metabolic liver disease, psychiatric conditions, and weight management.<\/p>\n<p>The <i>APOE<\/i> gene is among the most studied genetic risk factors in neurodegeneration, and <i>APOE<\/i> status is increasingly used to inform eligibility, safety monitoring, and risk stratification in Alzheimer\u2019s disease trials. It also carries relevance for cardiovascular and lipid-related research. Under the agreement, Charter Research\u2019s sites will be able to use Niki BioSolutions\u2019 testing platform, which is accredited by the College of American Pathologists (CAP) and approved by the New York State Clinical Laboratory Evaluation Program (CLEP), to bring validated genotyping results into their trial operations.<\/p>\n<p>Charter Research operates research centers in Orlando and The Villages, Florida, and in Chicago, Illinois, and has served as an investigative site for late-stage Alzheimer\u2019s disease programs. The agreement pairs that site network with a laboratory partner equipped to deliver the genetic data that modern Alzheimer\u2019s protocols increasingly require.<\/p>\n<p>\u201cAPOE status has moved from a research target to a practical necessity in Alzheimer\u2019s trials. It informs who enrolls, how participants are monitored, and how results are interpreted, making it a routine but critical step in how these studies are designed and run,\u201d said Alidad Mireskandari, Ph.D., President and COO of Niki BioSolutions. \u201cWe are pleased to support Charter Research\u2019s investigators and the study participants at their centers, and we see this agreement as another step in building Niki BioSolutions into a trusted testing resource for serious disease research\u201d.<\/p>\n<p>\n        <b>About Niki BioSolutions<\/b>\n      <\/p>\n<p>Niki BioSolutions is a clinical-stage life sciences company focused on unmet medical needs, providing high-quality genomic and biomarker testing solutions to healthcare providers, research institutions, and life sciences organizations through its CLIA-certified, CAP-accredited laboratory. The company combines proprietary technologies with a commitment to scientific rigor to support precision medicine across a range of therapeutic areas. Niki BioSolutions collaborates with leading academic centers, disease foundations, and biopharma companies.<\/p>\n<p>\n        <b>About Charter Research<\/b>\n      <\/p>\n<p>Charter Research is a clinical research site network that partners with pharmaceutical companies and study volunteers to evaluate new investigational treatments. Its research centers in Orlando and The Villages, Florida, and Chicago, Illinois, conduct clinical trials in Alzheimer\u2019s disease, Parkinson\u2019s disease, metabolic liver disease, psychiatric conditions, and weight loss. More information is available at CharterResearch.com.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ctarget,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cpropose,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cforecast,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cseek,\u201d \u201cfuture,\u201d \u201coutlook,\u201d and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, Niki BioSolutions\u2019 ability to successfully operate its business and provide value to stockholders; Niki BioSolutions\u2019 future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing or future ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to Niki BioSolutions and its industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for increasing revenue and executing growth initiatives. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industries in which Niki BioSolutions operates may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which Niki BioSolutions operates, the financial markets, economic, business and regulatory factors, and other factors, such as Niki BioSolutions\u2019 ability to execute on its strategies. More detailed information about risk factors can be found in the registration statement on Form S-4 filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on October 6, 2025 (File No. 333-290742), and in other reports filed under the company\u2019s prior name, Aptorum Group Limited, and that will be filed by Niki BioSolutions with the SEC. Niki BioSolutions does not undertake any duty to update forward-looking statements after the date of this press release.<\/p>\n<p>\n        <b>Investor Contact:<\/b><br \/>\n        <br \/>Lytham Partners, LLC<br \/>Ben Shamsian<br \/>646-829-9701<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTk1MSM3OTEyODQxIzUwMDEzMTQwMg==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NGJhMDhkMDktN2ZlOS00YmEyLWFkZjQtMGE2N2FhNTVmNWZiLTUwMDEzMTQwMi0yMDI2LTEwLTIzLWVu\/tiny\/Niki-BioSolutions-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Agreement brings CAP and NYS CLEP-approved genotyping test to a multi-site Alzheimer\u2019s clinical research network PRINCETON, NJ, NEW HAVEN, CT and ORLANDO, FL, Oct. 23, 2026 (GLOBE NEWSWIRE) &#8212; Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs through advanced genomic and biomarker testing, today announced that DiamiR Biosciences, its wholly owned subsidiary, has signed an agreement to perform apolipoprotein E (APOE) genotyping for Charter Research, a multi-site clinical research organization that conducts trials in Alzheimer\u2019s disease, Parkinson\u2019s disease, metabolic liver disease, psychiatric conditions, and weight management. The APOE gene is among the most studied genetic risk factors in neurodegeneration, and APOE status is increasingly used to inform eligibility, safety monitoring, and risk stratification &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1013090","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Agreement brings CAP and NYS CLEP-approved genotyping test to a multi-site Alzheimer\u2019s clinical research network PRINCETON, NJ, NEW HAVEN, CT and ORLANDO, FL, Oct. 23, 2026 (GLOBE NEWSWIRE) &#8212; Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs through advanced genomic and biomarker testing, today announced that DiamiR Biosciences, its wholly owned subsidiary, has signed an agreement to perform apolipoprotein E (APOE) genotyping for Charter Research, a multi-site clinical research organization that conducts trials in Alzheimer\u2019s disease, Parkinson\u2019s disease, metabolic liver disease, psychiatric conditions, and weight management. The APOE gene is among the most studied genetic risk factors in neurodegeneration, and APOE status is increasingly used to inform eligibility, safety monitoring, and risk stratification &hellip; Continue reading &quot;Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-23T12:06:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTk1MSM3OTEyODQxIzUwMDEzMTQwMg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research\",\"datePublished\":\"2026-10-23T12:06:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\\\/\"},\"wordCount\":859,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTk1MSM3OTEyODQxIzUwMDEzMTQwMg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\\\/\",\"name\":\"Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTk1MSM3OTEyODQxIzUwMDEzMTQwMg==\",\"datePublished\":\"2026-10-23T12:06:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTk1MSM3OTEyODQxIzUwMDEzMTQwMg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTk1MSM3OTEyODQxIzUwMDEzMTQwMg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/","og_locale":"en_US","og_type":"article","og_title":"Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research - Market Newsdesk","og_description":"Agreement brings CAP and NYS CLEP-approved genotyping test to a multi-site Alzheimer\u2019s clinical research network PRINCETON, NJ, NEW HAVEN, CT and ORLANDO, FL, Oct. 23, 2026 (GLOBE NEWSWIRE) &#8212; Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs through advanced genomic and biomarker testing, today announced that DiamiR Biosciences, its wholly owned subsidiary, has signed an agreement to perform apolipoprotein E (APOE) genotyping for Charter Research, a multi-site clinical research organization that conducts trials in Alzheimer\u2019s disease, Parkinson\u2019s disease, metabolic liver disease, psychiatric conditions, and weight management. The APOE gene is among the most studied genetic risk factors in neurodegeneration, and APOE status is increasingly used to inform eligibility, safety monitoring, and risk stratification &hellip; Continue reading \"Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-23T12:06:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTk1MSM3OTEyODQxIzUwMDEzMTQwMg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research","datePublished":"2026-10-23T12:06:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/"},"wordCount":859,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTk1MSM3OTEyODQxIzUwMDEzMTQwMg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/","name":"Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTk1MSM3OTEyODQxIzUwMDEzMTQwMg==","datePublished":"2026-10-23T12:06:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTk1MSM3OTEyODQxIzUwMDEzMTQwMg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTk1MSM3OTEyODQxIzUwMDEzMTQwMg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1013090"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013090\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1013090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1013090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1013090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}